PHARMAESSENTIA
PharmaEssentia develops treatments for myeloproliferative neoplasms, hepatitis and other diseases.
PHARMAESSENTIA
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2003-01-01
Address:
Taipei, T'ai-pei, Taiwan
Country:
Taiwan
Website Url:
http://www.pharmaessentia.com
Total Employee:
51+
Status:
Active
Contact:
+886-2-2655-7688
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Wordpress Plugins Mobile Non Scaleable Content
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Current Employees Featured
Founder
Stock Details
Investors List
Taiwania Capital Management Corporation
Taiwania Capital Management Corporation investment in Post-IPO Equity - PharmaEssentia
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-03 | PharmaEssentia Appoints Dr. Lih-Ling Lin as Chief Scientific Officer |
Official Site Inspections
http://www.pharmaessentia.com Semrush global rank: 1.87 M Semrush visits lastest month: 11.86 K
- Host name: 156.208.209.35.bc.googleusercontent.com
- IP address: 35.209.208.156
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "PharmaEssentia"
Executives - About Us - PharmaEssentia โฆ
PharmaEssentia develops treatments for myeloproliferative neoplasms, hepatitis and other diseases. The Companyโs world-class cGMP biologics facility in Taichung is certified by the Taiwan Food and Drug Administration (TFDA) and โฆSee details»
About PharmaEssentia - About Us - PharmaEssentia โฆ
2022. Oct PharmaEssentia hold the groundbreaking ceremony of the Zhubei plant.; Jun PharmaEssentia honored at the National Organization of Rare Disorders (NORD®) 2022 Rare Impact Awards for the introduction of โฆSee details»
PharmaEssentia - Crunchbase Company Profile
Organization. PharmaEssentia . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ...See details»
Corporate Governance Structure - Corporate Governance
PharmaEssentia develops treatments for myeloproliferative neoplasms, hepatitis and other diseases. The Companyโs world-class cGMP biologics facility in Taichung is certified by the โฆSee details»
Org Chart PharmaEssentia - The Official Board
Organizational Chart of PharmaEssentia. PharmaEssentia www.pharmaessentia.com. has 30 executives and 1 subsidiary +86 108 571 1234; Add an executive. PharmaEssentia (6446) โฆSee details»
PharmaEssentia - LinkedIn
PharmaEssentia | 13,282 followers on LinkedIn. Better Science, Better Lives. | PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical ...See details»
PharmaEssentia Medical Affairs
The PharmaEssentia Medical Affairs team is a strategic thought partner dedicated to providing comprehensive educational, clinical, and scientific information about PharmaEssentia โฆSee details»
PharmaEssentia Corp. - LinkedIn
PharmaEssentia Corp. Biotechnology Research Taipei ,Nangang District, Taipei 450 followers Better science, Better lives.See details»
PharmaEssentia - Contacts, Employees, Board Members, Advisors โฆ
PharmaEssentia develops treatments for myeloproliferative neoplasms, hepatitis, and other diseases.See details»
PharmaEssentia Corp. 2020 Annual Report
E-mail: [email protected] Tel: 886-2-2655-7688 Acting Spokesperson: Muriel Hwang Title: Senior Manager E-mail: [email protected] Tel: 886-2-2655-7688 2. The address and โฆSee details»
PharmaEssentia-Ropeginterferon alfa-2b,P1101,PV,polycythemia โฆ
PharmaEssentia develops treatments for myeloproliferative neoplasms, hepatitis and other diseases. The Companyโs world-class cGMP biologics facility in Taichung is certified by the โฆSee details»
2025 Archives - PharmaEssentia
Jan 23, 2025 Ray Urbanski joined PharmaEssentia in 2020 as SVP and Head of Clinical Development and Medical Affairs for the U.S. organization. An established clinical researcher, โฆSee details»
PharmaEssentia - Craft
Mar 27, 2024 PharmaEssentia (่ฅ่ฏ้ซ่ฅ่กไปฝๆ้ๅ ฌๅธ) is a biotech company focused on the areas of hematology, oncology, dermatology, and infectious diseases. Its lead compound is โฆSee details»
PharmaEssentia | Our Focus | Novel Treatments for MPNs
Ray Urbanski joined PharmaEssentia in 2020 as SVP and Head of Clinical Development and Medical Affairs for the U.S. organization. An established clinical researcher, licensed clinician โฆSee details»
PharmaEssentia 2025 Company Profile: Stock Performance
PharmaEssentia was founded in 2003. Where is PharmaEssentia headquartered? PharmaEssentia is headquartered in Taipei, Taiwan. What is the size of PharmaEssentia? โฆSee details»
PHARMAESSENTIA USA EXPANDS LEADERSHIP WITH EXECUTIVE โฆ
โWith tremendous progress just in the last year, our U.S. organization is now expanding a strong bench of leaders who bring expertise, passion and lessons from their careers to help us โฆSee details»
Company Highlights - PharmaEssentia
Aug 26, 2020 FDA completed inspection at PharmaEssentia US office and the CRO company, Brightech International Aug Korea orphan designation received Aug Besremi available in โฆSee details»
PharmaEssentia receives China NMPA approval for key Phase III โฆ
16 hours ago PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the โฆSee details»
FORTUNE Magazine: PharmaEssentia โ Leading Taiwanese Biotech โฆ
PharmaEssentia develops treatments for myeloproliferative neoplasms, hepatitis and other diseases. The Companyโs world-class cGMP biologics facility in Taichung is certified by the โฆSee details»
PharmaEssentia Gets Nod for Advanced Trial of Blood Cancer Drug
20 hours ago PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the โฆSee details»